期刊的影响因子--文章列表

期刊文章列表
Shuai Yang^1,2，Lu Chen^1,2，Ying Tong^1,2，Wenqiang Yu^1,2（Laboratory of RNA Epigenetics,Institutes of Biomedical Sciences & Shanghai Public Health Clinical Center & Department of General Surgery,Huashan Hospital,Cancer Metastasis Institute,Shanghai Medical College,Fudan University；Shanghai Key Laboratory of Medical Epigenetics）.Viral miRNA-mediated activation of hyaluronan production as a drug target against COVID-19[J].Acta Pharmaceutica Sinica B,2022,第7期 Yunhao Wu，Xiu Yu，Yuwei Wang，Yalin Huang，Jiahui Tang，Shuaishuai Gong，Siyu Jiang，Yuanli Xia，Fang Li，Boyang Yu，Yuanyuan Zhang，Junping Kou（State Key Laboratory of Natural Medicines）.Author correction to'Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TL R4 signaling’[Acta Pharmaceutica Sinica B 12(2022)1198-1212][J].药学学报(英文版),2022,第7期 Editoral Office of Acta Pharmaceutica Sinica（Editoral Office of Acta Pharmaceutica Sinica）.Information for Authors[J].Acta Pharmaceutica Sinica B,2022,第7期 Haiming Xiao^1,2，Xiaohong Sun¹，Zeyuan Lin¹，Yan Yang¹，Meng Zhang^1,2，Zhanchi Xu³，Peiqing Liu^1,2，Zhongqiu Liu³，Heqing Huang^1,2（Laboratory of Pharmacology & Toxicology，School of Pharmaceutical Sciences，Sun Yat-sen University；National and Local United Engineering Lab of Druggability and New Drugs Evaluation，School of Pharmaceutical Sciences，Sun Yat-sen University；School of Pharmaceutical Sciences，Guangzhou University of Chinese Medicine）.Gentiopicroside targets PAQR3 to activate the PI3K/AKT signaling pathway and ameliorate disordered glucose and lipid metabolism[J].Acta Pharmaceutica Sinica B,2022,第6期 Xiliang Du¹，Chiara Di Malta^2,3，Zhiyuan Fang¹，Taiyu Shen¹，Xiaodi Niu⁴，Meng Chen¹，Bo Jin¹，Hao Yu¹，Lin Lei¹，Wenwen Gao¹，Yuxiang Song¹，Zhe Wang¹，Chuang Xu⁵，Zhijun Cao⁶，Guowen Liu¹，Xinwei Li¹（Key Laboratory of Zoonosis，Ministry of Education，College of Veterinary Medicine，Jilin University；Telethon Institute of Genetics and Medicine (TIGEM) Via Campi Flegrei 34；Medical Genetics Unit，Department of Medical and Translational Science，Federico Ⅱ University；College of Food Science and Engineering，Jilin University；College of Animal Science and Veterinary Medicine，Heilongjiang Bayi Agricultural University；State Key Laboratory of Animal Nutrition，Beijing Engineering Technology Research Center of Raw Milk Quality and Safety Control，College of Animal Science and Technology，China Agricultural University）.Nuciferine protects against high-fat diet-induced hepatic steatosis and insulin resistance via activating TFEB-mediated autophagy——lysosomal pathway[J].Acta Pharmaceutica Sinica B,2022,第6期 Yun Yang¹，Danrong Hu¹，Yi Lu²，Bingyang Chu¹，Xinlong He¹，Yu Chen¹，Yao Xiao¹，Chengli Yang¹，Kai Zhou¹，Liping Yuan¹，Zhiyong Qian¹（State Key Laboratory of Biotherapy and Cancer Center，West China Hospital，Sichuan University，Collaborative Innovation Center of Biotherapy；West China School of Pharmacy，Sichuan University）.Tumor-targeted/reduction-triggered composite multifunctional nanoparticles for breast cancer chemo-photothermal combinational therapy[J].Acta Pharmaceutica Sinica B,2022,第6期 Jiajia Xu¹，Wei Du¹，Yunhe Zhao²，Kahleong Lim³，Li Lu²，Chengwu Zhang^1,4，Lin Li^1,5（Key Laboratory of Flexible Electronics (KLOFE) & Institute of Advanced Materials (IAM)，Jiangsu National Synergetic Innovation Center for Advanced Materials (SICAM)，Nanjing Tech University (Nanjing Tech)；Department of Anatomy，Shanxi Medical University；Lee Kang Chian School of Medicine，Nanyang Technological University；School of Basic Medical Sciences，Shanxi Medical University；The Institute of Flexible Electronics (IFE，Future Technologies)，Xiamen University）.Mitochondria targeting drugs for neurodegenerative diseases——Design, mechanism and application[J].Acta Pharmaceutica Sinica B,2022,第6期 Jingya Zhao，Huabei Huang，Jinyan Zhao，Xiang Xiong，Sibo Zheng，Xiaoqing Wei，Shaobing Zhou（Key Laboratory of Advanced Technologies of Materials，Ministry of Education，School of Materials Science and Engineering，Southwest Jiaotong University）.A hybrid bacterium with tumor-associated macrophage polarization for enhanced photothermal-immunotherapy[J].Acta Pharmaceutica Sinica B,2022,第6期 Ying Wu¹，Congying Pu²，Yixian Fu²，Guoqiang Dong¹，Min Huang²，Chunquan Sheng¹（School of Pharmacy，Second Military Medical University；State Key Laboratory of Drug Research，Shanghai Institute of Materia Medica，Chinese Academy of Sciences，University of Chinese Academy of Sciences）.NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion[J].Acta Pharmaceutica Sinica B,2022,第6期 Jiayi Ye^1,2，Bo Hou^1,3，Fangmin Chen^1,2，Shunan Zhang^1,3，Muya Xiong^2,4，Tianliang Li¹，Yechun Xu^2,4,5，Zhiai Xu³，Haijun Yu^1,2（State Key Laboratory of Drug Research & Center of Pharmaceutics，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；University of Chinese Academy of Sciences；School of Chemistry and Molecular Engineering，East China Normal University；CAS Key Laboratory of Receptor Research，and Drug Discovery and Design Center，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；School of Pharmaceutical Science and Technology，Hangzhou Institute for Advanced Study，University of Chinese Academy of Sciences）.Bispecific prodrug nanoparticles circumventing multiple immune resistance mechanisms for promoting cancer immunotherapy[J].Acta Pharmaceutica Sinica B,2022,第6期 Wei Wang¹，Shuo Feng²，Zhuyifan Ye¹，Hanlu Gao¹，Jinzhong Lin²，Defang Ouyang¹（State Key Laboratory of Quality Research in Chinese Medicine，Institute of Chinese Medical Sciences，University of Macau；State Key Laboratory of Genetic Engineering，School of Life Sciences，Zhongshan Hospital，Fudan University）.Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm[J].Acta Pharmaceutica Sinica B,2022,第6期 Yamin Li^1,2，Zhongfeng Ye¹，Hanyi Yang¹，Qiaobing Xu¹（Department of Biomedical Engineering，Tufts University；Department of Pharmacology，State University of New York，Upstate Medical University）.Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins,and drugs[J].Acta Pharmaceutica Sinica B,2022,第6期 Tingting Yang¹，Yuzhu Hu^1,2，Junming Miao¹，Jing Chen¹，Jiagang Liu¹，Yongzhong Cheng¹，Xiang Gao¹（Department of Neurosurgery and Institute of Neurosurgery，State Key Laboratory of Biotherapy and Cancer Center，West China Hospital，West China Medical School，Sichuan University and Collaborative Innovation Center for Biotherapy；Department of Medical Oncology，State Key Laboratory of Biotherapy and Cancer Center，West China Hospital，West China Medical School，Sichuan University and Collaborative Innovation Center for Biotherapy）.A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation,apoptosis and M2 macrophages polarization[J].Acta Pharmaceutica Sinica B,2022,第6期 Yurong Lai¹，Xiaoyan Chu²，Li Di³，Wei Gao^2,4，Yingying Guo⁵，Xingrong Liu^6,1，Chuang Lu⁷，Jialin Mao⁸，Hong Shen⁹，Huaping Tang¹⁰，Cindy Q.Xia¹¹，Lei Zhang¹²，Xinxin Ding¹³（Drug Metabolism，Gilead Sciences Inc.；Department of Pharmacokinetics，Pharmacodynamics and Drug Metabolism，Merck & Co.，Inc.；Pharmacokinetics，Dynamics and Metabolism，Pfizer Worldwide Research and Development；Translational Medicine，EMD Serono Research & Development Institute，Inc.；Eli Lilly and Company；Drug Metabolism and Pharmacokinetics Drug Metabolism and Pharmacokinetics，Accent Therapeutics，Inc. Department of Drug Metabolism and Pharmacokinetics，Genentech，A Member of the Roche Group；Drug Metabolism and Pharmacokinetics Department，Bristol-Myers Squibb Company；Bioanalysis and Biomarkers，Glaxo Smith Kline；Department of Drug Metabolism and Pharmacokinetics，Takeda Pharmaceuticals International Co.；Office of Research and Standards，Office of Generic Drugs，CDER，FDA；Department of Pharmacology and Toxicology，College of Pharmacy，University of Arizona）.Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development[J].Acta Pharmaceutica Sinica B,2022,第6期 Ozioma Udochukwu Akakuru¹，Zhoujing Zhang²，M.Zubair Iqbal^1,3，Chengjie Zhu¹，Yewei Zhang²，Aiguo Wu¹（Cixi Institute of Biomedical Engineering，International Cooperation Base of Biomedical Materials Technology and Application，Chinese Academy of Sciences (CAS) Key Laboratory of Magnetic Materials and Devices，Zhejiang Engineering Research Center for Biomedical Materials，Ningbo Institute of Materials Technology and Engineering，CAS；School of Medicine，Southeast University；School of Materials Science and Engineering，Zhejiang Sci-Tech University）.Chemotherapeutic nanomaterials in tumor boundary delineation：Prospects for effective tumor treatment[J].Acta Pharmaceutica Sinica B,2022,第6期 Zhiran Ju^1,2，Menglan Li¹，Junde Xu¹，Daniel C.Howell¹，Zhiyun Li¹，Fen-Er Chen^1,3,4（Institute of Pharmaceutical Science and Technology，Zhejiang University of Technology；Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals，Zhejiang University of Technology；Engineering Center of Catalysis and Synthesis for Chiral Molecules，Fudan University；Shanghai Engineering Center of Industrial Asymmetric Catalysis for Chiral Drugs）.Recent development on COX-2 inhibitors as promising anti-inflammatory agents：The past 10 years[J].Acta Pharmaceutica Sinica B,2022,第6期 Jiao Xue，Yining Zhu，Shuting Bai，Chunting He，Guangsheng Du，Yuandong Zhang，Yao Zhong，Wenfei Chen，Hairui Wang，Xun Sun（Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province，Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology，West China School of Pharmacy，Sichuan University）.Nanoparticles with rough surface improve the therapeutic effect of photothermal immunotherapy against melanoma[J].Acta Pharmaceutica Sinica B,2022,第6期 Menghuan Tang^1,2，Kai Lin^2,3，Mythili Ramachandran²，Longmeng Li²，Hongye Zou²，Huzhi Zheng¹，Zhao Ma^2,4，Yuanpei Li²（Key Laboratory of Luminescent and Real-Time Analytical Chemistry，Ministry of Education，College of Chemistry and Chemical Engineering，Southwest University；Department of Biochemistry and Molecular Medicine，UC Davis School of Medicine；College of Food Science and Engineering，Ocean University of China；Department of Medicinal Chemistry，Key Laboratory of Chemical Biology (MOE)，School of Pharmaceutical Sciences，Cheeloo College of Medicine，Shandong University）.A mitochondria-targeting lipid——small molecule hybrid nanoparticle for imaging and therapy in an orthotopic glioma model[J].Acta Pharmaceutica Sinica B,2022,第6期 Debin Zheng¹，Jingfei Liu¹，Limin Xie¹，Yuhan Wang¹，Yinghao Ding²，Rong Peng¹，Min Cui³，Ling Wang²，Yongjie Zhang³，Chunqiu Zhang¹，Zhimou Yang¹（Key Laboratory of Bioactive Materials，Ministry of Education，State Key Laboratory of Medicinal Chemical Biology，College of Life Sciences，Collaborative Innovation Center of Chemical Science and Engineering，National Institute of Functional Materials，Nankai University；College of Pharmacy，Nankai University；Department of Human Anatomy，Nanjing Medical University）.Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death[J].Acta Pharmaceutica Sinica B,2022,第6期 Lichan Tu^1,2,3，Xinbo Cai²，Yifeng Zhang^1,2，Yuru Tong⁴，Jian Wang⁵，Ping Su^5,6，Yun Lu²，Tianyuan Hu⁷，Yunfeng Luo²，Xiaoyi Wu²，Dan Li⁴，Luqi Huang⁵，Wei Gao^1,2（Beijing Shijitan Hospital，Capital Medical University；School of Traditional Chinese Medicine，Capital Medical University；School of Medicine，Zhejiang University City College；School of Pharmaceutical Sciences，Capital Medical University；State Key Laboratory Breeding Base of Dao-di Herbs，National Resource Center for Chinese Materia Medica，China Academy of Chinese Medical Sciences；Department of Chemistry，The Scripps Research Institute；School of Pharmacy，Hangzhou Normal University）.Mechanistic analysis for the origin of diverse diterpenes in Tripterygium wilfordii[J].Acta Pharmaceutica Sinica B,2022,第6期 Fangfang Lai¹，Ming Ji¹，Lei Huang¹，Yunchen Wang¹，Nina Xue¹，Tingting Du¹，Kai Dong²，Xiaoqing Yao²，Jing Jin¹，Zhiqiang Feng³，Xiaoguang Chen¹（Department of Pharmacology，State Key Laboratory of Bioactive Substances and Functions of Natural Medicines，Institute of Materia Medica，Chinese Academy of Medical Sciences and Peking Union Medical College；Tianjin Chase Sun Pharmaceutical Co.，Ltd.；Department of Pharmacochemistry，Institute of Materia Medica，Chinese Academy of Medical Sciences and Peking Union Medical College）.YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer[J].Acta Pharmaceutica Sinica B,2022,第6期 Jiaxing Li^1,2，Xiao Wang^1,2，Jiayu Ding^1,2，Yasheng Zhu^1,2，Wenjian Min^1,2，Wenbing Kuang^1,2，Kai Yuan^1,2，Chengliang Sun^1,2，Peng Yang^1,2（State Key Laboratory of Natural Medicines and Jiang Su Key Laboratory of Drug Design and Optimization，China Pharmaceutical University；Department of Medicinal Chemistry，School of Pharmacy，China Pharmaceutical University）.Development and clinical advancement of small molecules for ex vivo expansion of hematopoietic stem cell[J].Acta Pharmaceutica Sinica B,2022,第6期 Peilu Song^1,2，Fan Zhao³，Dahong Li^1,4，Jiqiang Qu⁵，Miao Yao⁶，Yuan Su¹，Hanxun Wang¹，Miaomiao Zhou⁶，Yujie Wang¹，Yinli Gao¹，Feng Li⁷，Dongmei Zhao¹，Fengjiao Zhang⁶，Yu Rao²，Mingyu Xia⁵，Haitao Li³，Jian Wang¹，Maosheng Cheng¹（Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education，Shenyang Pharmaceutical University；MOE Key Laboratory of Protein Sciences，School of Pharmaceutical Sciences，MOE Key Laboratory of Bioorganic Phosphorus Chemistry Chemical Biology，Tsinghua University；MOE Key Laboratory of Protein Sciences，Beijing Advanced Innovation Center for Structural Biology，Tsinghua-Peking Joint Center for Life Sciences，School of Life Sciences and School of Medicine，Tsinghua University；School of Traditional Chinese Materia Medica，Shenyang Pharmaceutical University；School of Life Science and Biopharmaceutics，Shenyang Pharmaceutical University；Wuya College of Innovation，Shenyang Pharmaceutical University；Department of Cell Biology，Key Laboratory of Cell Biology，Ministry of Public Health，and Key Laboratory of Medical Cell Biology，Ministry of Education，China Medical University）.Synthesis of selective PAK4 inhibitors for lung metastasis of lung cancer and melanoma cells[J].Acta Pharmaceutica Sinica B,2022,第6期 Shanmin Zheng^1,2，Jiawei Guo²，Fangyuan Cheng²，Zhengquan Gao³，Lei Du²，Chunxiao Meng¹，Shengying Li^2,4，Xingwang Zhang²（School of Life Sciences，Shandong University of Technology；State Key Laboratory of Microbial Technology，Shandong University；School of Pharmacy，Binzhou Medical University；Laboratory for Marine Biology and Biotechnology，Qingdao National Laboratory for Marine Science and Technology）.Cytochrome P450s in algae：Bioactive natural product biosynthesis and light-driven bioproduction[J].Acta Pharmaceutica Sinica B,2022,第6期 Ying Liu^1,2，Yu Han³，Shizhu Chen⁴，Jingjie Liu²，Dajiang Wang²，Yifei Huang²（Department of Ophthalmology，Beijing Rehabilitation Hospital，Capital Medical University；Department of Ophthalmology，Chinese PLA General Hospital；College of Chemistry & Environmental Science，Chemical Biology Key Laboratory of Hebei Province，Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education，Hebei University；China Resources Pharmaceutical Group Limited）.Liposome-based multifunctional nanoplatform as effective therapeutics for the treatment of retinoblastoma[J].Acta Pharmaceutica Sinica B,2022,第6期 Tingting Jiang，Guan Wang，Yao Liu，Lu Feng，Meng Wang，Jie Liu，Yi Chen，Liang Ouyang（State Key Laboratory of Biotherapy and Cancer Center；State Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery）.Author correction to“Development of small-molecule tropomyosin receptor kinase(TRK)inhibitors for NTRK fusion cancers”[Acta Pharmaceutica Sinica B 11(2021)355e372][J].药学学报(英文版),2022,第6期 Ting Lei，Zhihang Yang，Xue Xia，Yuxiu Chen，Xiaotong Yang，Rou Xie，Fan Tong，Xiaolin Wang，Huile Gao（Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province；School of Pharmacy and State Key Laboratory of Quality Research in Chinese Medicine）.Author correction to “A nanocleaner specifically penetrates the blood‒brain barrier at lesions to clean toxic proteins and regulate inflammation in Alzheimer’s disease” [Acta Pharmaceutica Sinica B 12，(2021) 4032e4044][J].药学学报(英文版),2022,第6期首页上一页 3 4 5 6 7 下一页尾页共有12页，转到页

期刊文章列表